Join Alicia and Lizette as they speak with Dr. Marc Braunstein, a Board-certified hematologist, medical oncologist at NYU Winthrop in New York, NY. This is episode four of our five- part episode series, ‘Removing Mystery from Myeloma‘. On this episode, Dr. Braunstein explains how management of myeloma differs between younger and older patients. He stresses how treatment is not solely based on age and shares the other factors that are taken into consideration when determining how a patient may respond to treatment. Dr. Braunstein discusses minimal residual disease (MRD), the role of autologous and allogeneic transplant for myeloma patients and the difference between palliative and hospice care.
Be sure to listen to our other episodes from this series. The fifth episode will be launching this Spring.
Podcast: Play in new window | Download
Subscribe: Google Podcasts | Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More
Mentioned on this episode:
- Myeloma
- Myeloma booklets
- Dana-Farber Cancer Institute’s PROMISE Study
- LLS Community
- Stem cell transplantation
- Graft-Versus-Host Disease
Other episodes from this series:
- Removing Mystery from Myeloma: Diagnosis & Treatment
- Removing Mystery from Myeloma: Questions to ask, Bone Health and Clinical Trials
- Removing Mystery from Myeloma: The Truth About Transplant
Additional LLS Support Resources:
- Information Specialists
- Free telephone/web patient programs
- Free booklets
- Financial support
- Caregiver support
- Support groups
- A Medication Resource for Myeloma Patients
Support for this episode provided by Amgen and Takeda.
